United States · Platforms & data · MarketBeat

Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts

Published by MarketBeat · United States 2 h ago

Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Own Costco Stock by Oct. 30 to Qualify for Its Nov. 13 Dividend. Here's How Many Shares You'd Need for $1,000 in Yearly Dividends.

Investing.com

SPACCircle Acquisition prices $100M IPO on Nasdaq

MarketWatch

‘You need only watch episodes of Judge Judy’: I’m in my 70s. Why do people keep making the same avoidable financial mistakes?

TheStreet

Banks are locking AI agents out, Hashgraph CIO Gregg Bell says blockchain is the way back in

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Morningstar